Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Part of paid clinical trials in Irving, Texas.

Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Study ID
NCT06504368
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DCR-PDL1 — DRUG
    Solution for IV Infusion

Study Details

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

Key Dates

Start date
May 29, 2024
Status verified
Nov 2025
Primary completion
Jun 1, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: DCR-PDL1
    Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.

Primary Outcome Measure

Incidence and Nature of Adverse Events (AEs) [ Time Frame: Baseline to week 8 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
NEXT OncologyIrvingTexas75039-
Next OncologySan AntonioTexas78229-

Find similar trials in Irving, TX

By research site
NEXT Oncology· Irving, TXNext Oncology· San Antonio, TX

Related Studies